<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2348">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641858</url>
  </required_header>
  <id_info>
    <org_study_id>BCG-COVID-RCT</org_study_id>
    <nct_id>NCT04641858</nct_id>
  </id_info>
  <brief_title>BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic</brief_title>
  <acronym>EDCTP</acronym>
  <official_title>BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Hygiene and Tropical Medicine, NOVA University, Lisbon, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Verde, Praia, Cape Verde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Public Health of Cape Verde, Praia, Cape Verde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigacao em Saude de Manhica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bandim Health Project, Bissau, Guinea-Bissau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic challenges available hospital capacity. Strategies to protect health&#xD;
      care workers (HCW) are desperately needed. Bacille Calmette- Guérin (BCG) has protective&#xD;
      non-specific effects against other infections; a plausible immunological mechanism has been&#xD;
      identified in terms of &quot;trained innate immunity&quot;.&#xD;
&#xD;
      The primary objective of the study is to evaluate whether BCG can reduce unplanned&#xD;
      absenteeism due to illness among HCW during the COVID-19 pandemic. Secondary objectives are&#xD;
      to reduce the number of HCW that are infected with COVID-19, reduce hospital admissions for&#xD;
      HCW and to improve the capacity for clinical research.&#xD;
&#xD;
      Design: Single-blind, parallel-group placebo-controlled multi-centre block randomized trial&#xD;
      including a total of 1050 HCW. The study sites will be the Manhiça hospital in Mozambique,&#xD;
      Central Hospital Dr. Agostinho Neto and Central Hospital Dr. Baptista de Sousa in Cape Verde&#xD;
      and Hospital Nacional Simão Mendes and other hospitals in the capital Bissau in&#xD;
      Guinea-Bissau. Population: HCW (nurses/physicians/others) ≥18 years.&#xD;
&#xD;
      Intervention: Block randomization 1:1 to intradermal standard dose (0.1 ml) of BCG vaccine or&#xD;
      placebo (saline). Endpoints: Primary: Days of unplanned absenteeism due to illness.&#xD;
      Secondary: Days of absenteeism because of documented COVID-19; cumulative incidence of&#xD;
      infectious disease hospitalizations.&#xD;
&#xD;
      Follow-up: mobile phone interviews every second week, regarding symptoms, absenteeism and&#xD;
      causes, COVID-19 testing (if done) and their results.&#xD;
&#xD;
      Perspectives: If BCG can reduce HCW absenteeism it has global implications. The intervention&#xD;
      can quickly be scaled up all over the world.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main hypothesis for this study is that BCG vaccination of HCW reduces unplanned&#xD;
      absenteeism due to illness by 20%.&#xD;
&#xD;
      Trial design Single-blind, parallel-group placebo-controlled adaptive multicentre trial, with&#xD;
      block-randomisation 1:1 (treatment:placebo) in blocks of 20 within strata defined by gender&#xD;
      (male/female) and occupational group (doctors/ nurses/other) to an intradermal standard 0.1&#xD;
      ml dose of BCG vaccine or placebo (saline) including a total of 1050 HCW (BCG arm and placebo&#xD;
      arm).&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Health Care Workers defined as a person who delivers care and services to the sick and ailing&#xD;
      either directly as doctors and nurses or indirectly as aides, helpers, laboratory&#xD;
      technicians, or even medical waste handlers.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      The intervention will consist of the administration of an intradermal injection of a standard&#xD;
      0.1 ml adult dose of attenuated Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish&#xD;
      strain 1331, 2-8 × 10*5 CFU or the placebo comparator: intradermal standard 0.1 ml saline&#xD;
      solution (NaCl 0.9%). Both BCG and saline solution will be injected in the skin over the&#xD;
      upper deltoid muscle.&#xD;
&#xD;
      Blinding:&#xD;
&#xD;
      The BCG vaccine will be administered by study physicians/nurses, who are not blinded but also&#xD;
      not involved in the data collection. Participants, data collectors and data entry clerks will&#xD;
      be blinded to the treatment allocation.&#xD;
&#xD;
      In case of serious adverse events, the participant can be unblinded after consultation with&#xD;
      the investigator or the vaccinating physician/nurse. When the study has ended, all&#xD;
      participants will receive information about the intervention that they received.&#xD;
&#xD;
      Follow-up:&#xD;
&#xD;
      Follow-up will last for 6 months (182 days). Every second week, participants will be&#xD;
      contacted over telephone and interviewed for symptoms and absenteeism from work. By the end&#xD;
      of follow-up, participants will be invited for another POC test for COVID-19 serology.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      The sample size was calculated on the basis of the primary hypothesis. A total of 1050 HCW&#xD;
      randomized with an estimated loss to follow-up of 5%, and a mean number of days off work due&#xD;
      to illness in the control group of 5 days (SD=5) over a 6-month period will demonstrate a&#xD;
      reduction among BCG vaccinated of 20% for a mean absence of 4 days (80% power and alpha&#xD;
      0.05). The estimated loss to follow-up (5%) was based on past telephone-based surveys&#xD;
      conducted in Mozambique and Bissau.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-center randomized placebo-controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants will be blinded to treatment. The physicians administering the BCG vaccine or placebo will not be blinded. Those assessing outcomes will be blinded to the randomization allocation. In case of serious adverse events, the participant can be unblinded after consultation with the coordinating PI or sponsor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Days of unplanned absenteeism due to illness</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Unplanned absenteeism is defined by being absent from work due to causes other than holidays, parental leave, and other planned leaves, family assistance (including mourning leave) and quarantine measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of unplanned absenteeism due to documented COVID-19</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Unplanned absenteeism is defined by being absent from work due to causes other than holidays, parental leave, and other planned leaves, family assistance (including mourning leave) and quarantine measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of hospital admissions due to illness (minus accidents).</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Hospital admissions involves staying at a hospital for at least one night or more for medical reasons. It includes admissions to hospital wards and overnight stays in emergency departments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Whether the participant died during follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalisation for COVID-19</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Refers to the number of nights of hospitalisation due to COVID-19</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalisation besides COVID-19</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Refers to the number of nights of hospitalisation due to other reasons besides COVID-19</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to hospitalisation</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Time, in days, from enrolment to first night of hospitalisation</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to absenteeism</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Time, in days, from enrolment to first day absent from work due to ill-health and disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to COVID-19 absenteeism</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Refers to the number of days since enrolment to first day absent from work due to suspected COVID-19</description>
  </other_outcome>
  <other_outcome>
    <measure>COVID-19 infection</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Describes if the participant is positive for SARS-CoV2 or has had COVID-19</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to COVID-19</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Time, in days, from enrolment to positive test for SARS-CoV2</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Covid19</condition>
  <condition>Morbidity</condition>
  <condition>Absenteeism</condition>
  <arm_group>
    <arm_group_label>BCG-Denmark</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the right upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color and appearance as the resuspended BCG vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG-Denmark</intervention_name>
    <description>Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.</description>
    <arm_group_label>BCG-Denmark</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  health care worker (physician, nurse, or other) based at one of the research&#xD;
             hospitals.&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy to (components of) BCG or serious adverse events to prior BCG&#xD;
             administration;&#xD;
&#xD;
          -  known previous, active or latent infection with Mycobacterium tuberculosis or other&#xD;
             mycobacterial species&#xD;
&#xD;
          -  fever (&gt;38 C) within past 24 hours;&#xD;
&#xD;
          -  previous confirmed COVID-19 (positive test - PCR or antibody);&#xD;
&#xD;
          -  suspicion of active viral or bacterial infection&#xD;
&#xD;
          -  severely immunocompromised subjects&#xD;
&#xD;
          -  self-reported HIV infection&#xD;
&#xD;
          -  self-reported pregnancy;&#xD;
&#xD;
          -  active solid or non-solid malignancy or lymphoma within the prior two years;&#xD;
&#xD;
          -  contraindications for live attenuated vaccine administration.&#xD;
&#xD;
          -  not having a mobile phone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Stabell Benn, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Stabell Benn, Professor</last_name>
    <phone>25883964</phone>
    <phone_ext>+45</phone_ext>
    <email>cbenn@health.sdu.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inês Fronteira, PhD</last_name>
    <phone>213 652 600</phone>
    <phone_ext>351</phone_ext>
    <email>ifronteira@ihmt.unl.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cape Verde</name>
      <address>
        <city>Praia</city>
        <state>Santiago</state>
        <zip>379C</zip>
        <country>Cape Verde</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabel Inês Araújo, Professor</last_name>
      <phone>9948948</phone>
      <phone_ext>238</phone_ext>
      <email>iniza.araujo@adm.unicv.edu.cv</email>
    </contact>
    <contact_backup>
      <last_name>Maria da Luz Lima</last_name>
      <phone>612167</phone>
      <phone_ext>238</phone_ext>
      <email>MariadaLuz.Lima@ms.gov.cv</email>
    </contact_backup>
    <investigator>
      <last_name>Isabel Inês Araújo, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bandim Health Project</name>
      <address>
        <city>Bissau</city>
        <state>SAB</state>
        <zip>1004</zip>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amabélia Rodrigues, MD, PhD</last_name>
      <phone>966078659</phone>
      <phone_ext>245</phone_ext>
      <email>a.rodrigues@bandim.org</email>
    </contact>
    <contact_backup>
      <last_name>Peter Aaby, DMSc</last_name>
      <phone>966731397</phone>
      <phone_ext>245</phone_ext>
      <email>p.aaby@bandim.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amabélia Rodrigues, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhiça Health Research Centre</name>
      <address>
        <city>Manhiça</city>
        <state>Maputo</state>
        <zip>1929</zip>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Aide, MD, MSc, PhD</last_name>
      <phone>21810002</phone>
      <phone_ext>258</phone_ext>
      <email>Pedro.Aide@manhica.net</email>
    </contact>
    <contact_backup>
      <last_name>Helio Mucavele, MD</last_name>
      <phone>21810002</phone>
      <phone_ext>258</phone_ext>
      <email>helio.mucavele@manhica.net</email>
    </contact_backup>
    <investigator>
      <last_name>Pedro Aide, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cape Verde</country>
    <country>Guinea-Bissau</country>
    <country>Mozambique</country>
  </location_countries>
  <reference>
    <citation>Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol. 2014 Oct;15(10):895-9. doi: 10.1038/ni.2961.</citation>
    <PMID>25232810</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Benn CS. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019 Dec;25(12):1459-1467. doi: 10.1016/j.cmi.2019.08.011. Epub 2019 Aug 23. Review.</citation>
    <PMID>31449870</PMID>
  </reference>
  <reference>
    <citation>Benn CS, Fisker AB, Rieckmann A, Sørup S, Aaby P. Vaccinology: time to change the paradigm? Lancet Infect Dis. 2020 Oct;20(10):e274-e283. doi: 10.1016/S1473-3099(19)30742-X. Epub 2020 Jul 6. Review.</citation>
    <PMID>32645296</PMID>
  </reference>
  <reference>
    <citation>Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, Diness BR, Lausch KR, Lund N, Biering-Sørensen S, Whittle H, Benn CS. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011 Jul 15;204(2):245-52. doi: 10.1093/infdis/jir240.</citation>
    <PMID>21673035</PMID>
  </reference>
  <reference>
    <citation>Biering-Sørensen S, Aaby P, Lund N, Monteiro I, Jensen KJ, Eriksen HB, Schaltz-Buchholzer F, Jørgensen ASP, Rodrigues A, Fisker AB, Benn CS. Early BCG-Denmark and Neonatal Mortality Among Infants Weighing &lt;2500 g: A Randomized Controlled Trial. Clin Infect Dis. 2017 Oct 1;65(7):1183-1190. doi: 10.1093/cid/cix525.</citation>
    <PMID>29579158</PMID>
  </reference>
  <reference>
    <citation>Higgins JP, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016 Oct 13;355:i5170. doi: 10.1136/bmj.i5170. Review. Erratum in: BMJ. 2017 Mar 8;356:j1241.</citation>
    <PMID>27737834</PMID>
  </reference>
  <reference>
    <citation>Rieckmann A, Villumsen M, Sørup S, Haugaard LK, Ravn H, Roth A, Baker JL, Benn CS, Aaby P. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. Int J Epidemiol. 2017 Apr 1;46(2):695-705. doi: 10.1093/ije/dyw120.</citation>
    <PMID>27380797</PMID>
  </reference>
  <reference>
    <citation>Wardhana, Datau EA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011 Jul;43(3):185-90.</citation>
    <PMID>21979284</PMID>
  </reference>
  <reference>
    <citation>Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.</citation>
    <PMID>29996082</PMID>
  </reference>
  <reference>
    <citation>Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ. Trained immunity: A program of innate immune memory in health and disease. Science. 2016 Apr 22;352(6284):aaf1098. doi: 10.1126/science.aaf1098. Epub 2016 Apr 21. Review.</citation>
    <PMID>27102489</PMID>
  </reference>
  <reference>
    <citation>Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, Kumar V, Xavier RJ, Wijmenga C, Joosten LAB, Reusken CBEM, Benn CS, Aaby P, Koopmans MP, Stunnenberg HG, van Crevel R, Netea MG. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5. doi: 10.1016/j.chom.2017.12.010.</citation>
    <PMID>29324233</PMID>
  </reference>
  <reference>
    <citation>Benn CS, Fisker AB, Whittle HC, Aaby P. Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review. EBioMedicine. 2016 Aug;10:312-7. doi: 10.1016/j.ebiom.2016.07.016. Epub 2016 Jul 15. Review.</citation>
    <PMID>27498365</PMID>
  </reference>
  <reference>
    <citation>Roth AE, Benn CS, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M, Whittle H, Aaby P. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ. 2010 Mar 15;340:c671. doi: 10.1136/bmj.c671.</citation>
    <PMID>20231251</PMID>
  </reference>
  <reference>
    <citation>Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, Peduto L, Thalmann GN, Albert ML. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012 Jun 6;4(137):137ra72. doi: 10.1126/scitranslmed.3003586.</citation>
    <PMID>22674550</PMID>
  </reference>
  <reference>
    <citation>Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom WA, Johnson JL. Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine. 2014 Jun 30;32(31):3982-8. doi: 10.1016/j.vaccine.2014.04.084. Epub 2014 May 9.</citation>
    <PMID>24814553</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Innate immune training</keyword>
  <keyword>Non-specific effects of BCG</keyword>
  <keyword>Heterologous effects</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to professor Inês Fronteira ifronteira@ihmt.unl.pt</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When follow-up has been completed and the dataset have been closed.</ipd_time_frame>
    <ipd_access_criteria>Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to ifronteira@ihmt.unl.pt</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

